Merck (and BP) never done any BOs with OTC-companies is simply the shorts and bashers narrative (or you prove it !) So, you are a short and basher ! Once a product is duly and correctly approved, there is no reason whatsoever for a BP-company to make this step.
You might be right. Merck passed over DCVax-L because Merck can have collaboration with Mayo Clinic which has been doing extensive research on DC vaccine therapy and delivered spectacular results. If Mayo Clinic can expand the allogeneic tumor lysate pool, the cost of DC vaccine therapy should be reduced significantly. I saw Matthew Vandermast's post was liked by Tim Talomie (Vice President, Oncology Global Marketing Human Health Division at Merck), Mickey Rego (Vice President, Business Development at Veranova), and Kevin Pavelko (Research Scientist at Mayo Clinic) who coauthored the following paper. Matthew Vandermast used to be the President of Oncovir. It seems like Merck, Veranova acquired by Merck, and Mayo Clinic have connection with Oncovir. They probably bypassed NWBO to have connection with Oncovir. In sum, Merck has no interest in $NWBO and the longs are doomed. Are you happy now?
Sponsor Mayo Clinic Study Start (Actual): 2017-11-15 Primary Completion (Actual): 2020-06-14 Principal Investigator:Matthew S. Block, M.D., Ph.D.,Mayo Clinic
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma https://clinicaltrials.gov/study/NCT01239875
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma https://clinicaltrials.gov/study/NCT03035331
Study Start (Actual): 2017-08-15 Primary Completion (Actual): 2022-01-25 Principal Investigator:Yi Lin, MD, PhD,Mayo Clinic
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer https://clinicaltrials.gov/study/NCT03942328 Study Start (Actual): 2019-09-19 Primary Completion (Estimated): 2027-08-31 Principal Investigator:Lewis R. Roberts, MD, PhD,Mayo Clinic in Rochester
Vaccine Therapy in Treating Patients With Recurrent Glioblastoma https://clinicaltrials.gov/study/NCT03360708 Sponsor Mayo Clinic Study Start (Actual): 2013-11-27 Primary Completion (Actual): 2021-06-02 Principal Investigator: Ian Parney,Mayo Clinic
Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma https://clinicaltrials.gov/study/NCT01957956 Study Start (Actual): 2013-11-11 Primary Completion (Actual): 2016-11-16 Principal Investigator: Ian Parney,Mayo Clinic
Folate Receptor Alpha Dendritic Cells (FRaDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial https://clinicaltrials.gov/study/NCT06639074 Study Start (Actual): 2024-11-08 Primary Completion (Estimated): 2027-12-31 Study Completion (Estimated): 2027-12-31
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (FRAPPE) https://clinicaltrials.gov/study/NCT05920798 Study Start (Actual): 2023-09-28 Primary Completion (Estimated): 2027-07-15 Study Completion (Estimated): 2027-07-15
Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer https://clinicaltrials.gov/study/NCT02111941 Study Start (Actual): 2014-04-14 Primary Completion (Actual): 2021-07-27 Study Completion (Actual): 2021-07-27
Market Data 
Markets 
AI
